All In Biotech

Drug Trial Radar · NCT06632262

A Phase 2 Clinical Study of ABSK061 and ABSK043

An Open-label Phase 2, Multicenter, Open-Label Clinical Study to Evaluate the Safety and Efficacy of ABSK061 and ABSK043 with or Without Chemotherapy in Patients with Metastatic/Unresectable Solid Tumors with FGFR2/3 Alterations

Last checked: Nov 19, 2026Latest source record: Nov 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

202

Planned (sponsor's estimate)

Start

Nov 13, 2024

Primary completion

Nov 30, 2029

Study completion Jun 30, 2030

Sponsor

Lead sponsor
Abbisko Therapeutics Co, LtdIndustry
Sponsor type
Industry
First posted
Oct 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the anti-tumor activity of ABSK061 + ABSK043 in terms of overall response rate (ORR) in in Patients with Metastatic/Unresectable Solid Tumors with FGFR2/3 Alterations

Conditions

  • HER2-Gastric/Gastroesophageal Junction Cancer
  • Urothelial Carcinoma
  • Non-Small Cell Lung Cancer
  • Solid Tumors

Interventions

  • ABSK061 + ABSK043Drug

    Participants with fibroblast growth factor receptor (FGFR) mutations and FGFR gene fusions will receive a dose of ABSK061 + ABSK043 oral capsule until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment, or end of data collection timepoint if there is clinical benefit in the opinion of the investigator, has been achieved.

  • ABSK061+ABSK043 in combination with CAPOXDrug

    Participants with HER2-Gastric/Gastroesophageal Junction Cancer and fibroblast growth factor receptor 2( FGFR2 ) amplification and overexpression will receive a dose of ABSK061 + ABSK043 oral capsule in combination with CAPOX until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment, or end of data collection timepoint if there is clinical benefit in the opinion of the investigator, has been achieved.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose limited toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 28 days)
  2. To assess the tolerability of ABSK061 + ABSK043 in combination with CAPOX in patients with first-line gastric/gastroesophageal junction cancerTime frame: At the end of Cycle 1 (each cycle is 21 days)
  3. To assess the anti-tumor activity of ABSK061 + ABSK043 in combination with CAPOX as the primary endpoint of Progression-free survival (PFS) in first-line treatment of patients with metastatic/unresectable HER2-gastric/gastroesophageal junction cancerTime frame: up to 5 years
  4. To assess the anti-tumor activity of ABSK061 + ABSK043 in patients with metastatic/unresectable urothelial cancer with FGFR2/3 activating alteration or FGFR3 overexpression, with Objective response rate (ORR) as the primary endpointTime frame: up to 5 years
  5. To assess the anti-tumor activity of ABSK061 + ABSK043 in patients with non-small cell lung cancer withFGFR2/3 activating alteration or overexpression as the primary endpointTime frame: up to 5 years
  6. To assess the anti-tumor activity of ABSK061 + ABSK043 in patients with metastatic/unresectable other advanced solid tumors with FGFR2/3 activatingon alteration or overexpression as the primary endpointTime frame: up to 5 years

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Changzhi People's Hospital

    Changzhi, China · Not yet recruiting

  • West China Hospital, Sichuan University

    Chengdu, China · Not yet recruiting

  • The First Hospital of China Medical University

    Hangzhou, China · Not yet recruiting

  • Zhejiang Provincial People'S Hospital

    Hangzhou, China · Not yet recruiting

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, China · Not yet recruiting

  • Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology

    Wuhan, China · Not yet recruiting

  • First Hospital of Shanxi Medical University

    Xi'an, China · Not yet recruiting

  • Shanxi Cancer hospital (Shanxi Cancer institute)

    Xi'an, China · Not yet recruiting

  • First Affiliated Hospital of Xiamen University

    Xiamen, China · Not yet recruiting

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, China · Not yet recruiting

  • Guizhou Provincial People'S Hospital

    Guiyang, Guizhou, China · Not yet recruiting

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China · Not yet recruiting

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Heibei, China · Not yet recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • Hunan Central Hospital

    Changsha, Hunan, China · Not yet recruiting

  • Jiangxi Cance Hospital

    Nanchang, Jiangxi, China · Not yet recruiting

  • Liaoning Cancer Hospital and Institute

    Shenyang, Liaoning, China · Not yet recruiting

  • Cancer Hospital of Shandong First Medical University

    Jinan, Shandong, China · Not yet recruiting

  • ZhongShan Hospital Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

  • Xiangyang Central Hospital

    Xiangyang, Sichuang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.